Zepbound for Sleep Apnea: The First Drug Ever Approved for OSA

For decades, the only effective treatments for obstructive sleep apnea were mechanical: CPAP machines, oral appliances, or surgery. There was no approved drug for the condition.

That changed on December 20, 2024, when the FDA approved Zepbound (tirzepatide) as the first prescription medication ever indicated for moderate-to-severe obstructive sleep apnea in adults with obesity.

What is obstructive sleep apnea?

Obstructive sleep apnea (OSA) occurs when the muscles at the back of the throat relax during sleep, causing the airway to narrow or close. This repeatedly stops breathing during the night - sometimes dozens or hundreds of times per hour.

OSA affects roughly 30 million adults in the United States. Its consequences include:

• Daytime fatigue and cognitive impairment
• Increased risk of high blood pressure, heart disease, and stroke
• Type 2 diabetes risk
• Depression and anxiety

Obesity is one of the strongest risk factors. Excess fat tissue, particularly around the neck and upper airway, contributes directly to airway collapse during sleep.

How does Zepbound treat sleep apnea?

The primary mechanism is weight loss. Tirzepatide (the active ingredient in Zepbound and Mounjaro) typically produces 15–22% body weight reduction. Losing this amount of weight significantly reduces the fat deposits that physically obstruct the airway.

But the SURMOUNT-OSA trials suggested the benefit may go beyond weight loss alone - GIP and GLP-1 receptors are present in tissues involved in upper airway muscle tone, and there may be direct effects on airway muscle function. Research into this is ongoing.

What did the clinical trials show?

The SURMOUNT-OSA program consisted of two Phase 3 trials in adults with moderate-to-severe OSA and obesity:

SURMOUNT-OSA Trial 1 (not using CPAP)

• 52 weeks
• Primary endpoint: change in apnea-hypopnea index (AHI) - the number of breathing disruptions per hour
• Tirzepatide 15 mg: AHI reduced by approximately 27.4 events/hour (62.2% reduction)
• Placebo: reduced by 4.8 events/hour

SURMOUNT-OSA Trial 2 (using CPAP)

• Same duration and design, but participants were continuing CPAP use
• Tirzepatide: AHI reduced by approximately 30.4 events/hour (62.8% reduction)
• Significant improvements in oxygen saturation, sleep quality, and patient-reported fatigue

Both trials also showed substantial weight loss (approximately 20%) and improvements in blood pressure and other cardiometabolic markers.

Who qualifies for Zepbound for sleep apnea?

The FDA approved Zepbound for this indication in adults who have both:

1. Moderate-to-severe obstructive sleep apnea - confirmed by a sleep study (AHI ≥ 15 events/hour)
2. Obesity - BMI ≥ 30

Patients with overweight (BMI 27–29.9) are not currently covered under this specific indication. The weight loss indication for Zepbound separately covers overweight patients with at least one comorbidity.

Can Zepbound replace CPAP?

This is the question most OSA patients want answered.

The SURMOUNT-OSA trials were not designed to test CPAP replacement directly. However, in Trial 1 (patients not using CPAP), Zepbound produced clinically significant reductions in AHI - and a meaningful proportion of patients reached what would normally be classified as mild or even resolved OSA.

In practice, whether you can discontinue CPAP depends on:

• Your baseline AHI severity
• How much weight you lose and maintain
• Whether your AHI on follow-up testing falls below the threshold for clinically significant OSA

Do not stop using CPAP without a repeat sleep study and your doctor's guidance. But for many patients with obesity-driven OSA, weight loss with Zepbound may eventually allow CPAP to be reduced or discontinued.

Insurance coverage for the sleep apnea indication

The sleep apnea approval opens up new insurance pathways. Some plans that previously denied Zepbound for obesity may now approve it under the OSA indication with appropriate documentation (sleep study results, BMI, diagnosis code).

Tracking sleep apnea improvement on Zepbound

OSA severity changes gradually over weeks and months as weight decreases. Logging weekly weight, injection doses, and noting any changes in sleep quality, daytime energy, or snoring gives you a practical picture of how the medication is working - useful both for self-monitoring and for your next clinical review.

Final takeaway

Zepbound became the first drug ever approved for obstructive sleep apnea in December 2024. It works primarily through weight loss, which directly reduces airway obstruction. Clinical trials showed a 62% average reduction in breathing disruptions per hour. If you have both obesity and moderate-to-severe OSA, discuss with your doctor whether Zepbound is appropriate for your situation.

Consult your healthcare provider before starting or changing any medication.

Sources

• Zepbound FDA approval for sleep apnea: drugs.com/history/zepbound.html
• SURMOUNT-OSA Trial 1 and 2 results: Lilly press releases, 2024
• Zepbound FDA approval announcement, December 20, 2024
• Sateia MJ. International classification of sleep disorders. Chest. 2014;146(5)